Mass Tort brief
Bench Trials, Verdicts, and Settlement Frameworks
Federal courts launch inaugural Camp Lejeune trials as major drug, cosmetic, and silica toxic torts approach pivotal bellwethers.
Mass Tort
California's dismissal of TDF injury claims eliminates Gilead's most dangerous state-level exposure — concentrating all drug-delay liability inside federal multidistrict court.
BackgroundTenofovir disoproxil fumarate (TDF) is an antiretroviral formulation widely used in HIV treatments such as Truvada and Atripla. Thousands of patients allege Gilead intentionally shelved safer tenofovir alafenamide (TAF) drugs for a decade to milk expiring patent monopolies.
- The dismissal with prejudice shields Gilead from California state court liability, removing a major venue where plaintiffs had secured strong pre-trial momentum.
- Parallel federal multidistrict actions remain fully active, with the first bellwether jury trial scheduled to test design-defect claims in September 2027.
- Plaintiffs assert internal company documents prove executives withheld the less toxic TAF compound despite knowing TDF caused irreversible bone density loss and kidney failure.
Mass Tort
The start of Camp Lejeune's first bench trials strips the government of delay tactics — forcing the Justice Department to commit to a global payout formula.
BackgroundThe 2022 Camp Lejeune Justice Act allows veterans and military families to seek compensation for illnesses caused by volatile organic compounds in base drinking water between 1953 and 1987. More than 3,700 federal lawsuits remain active in the Eastern District of North Carolina.
- U.S. District Judge Terrence Boyle is hearing the initial kidney cancer claim of veteran Frank Mousser, creating the first test case for judicial damage awards.
- Court-appointed Settlement Masters and federal attorneys face a judicial target to deliver a formula, seeking to avoid hundreds of individual base trials.
- The Justice Department has distributed over $879M under an administrative Elective Option process, but high refusal rates pushed thousands of veterans into federal court.
Mass Tort
J&J's $5.5B charge marks its capitulation to tort courts outside bankruptcy — ending years of legal maneuvering without guaranteeing the 95% claimant consensus needed to close.
BackgroundTens of thousands of women allege that Johnson & Johnson's cosmetic baby powder contained asbestos fibers that triggered ovarian cancer and mesothelioma. Federal courts repeatedly rejected the company's attempt to use subsidiary bankruptcy filings to cap its tort liability.
- The proposed settlement requires a strict 95% claimant participation rate, threatening to collapse the agreement if holdout plaintiff attorneys refuse the payout terms.
- Federal multidistrict proceedings in New Jersey remain paused for balloting, but independent state courts continue to try pending mesothelioma cases before juries.
- A Louisiana state jury ordered J&J to pay $10M in an individual talc case last week, highlighting the ongoing risk of non-MDL verdicts.
Mass Tort
Caesarstone's $33M defeat shows juries firmly reject workplace-safety defenses — making high-silica stone an unsustainable product liability for building-materials manufacturers.
BackgroundEngineered stone countertops contain up to 90% crystalline silica, which generates toxic micro-dust during cutting and dry fabrication that scars lung tissue. Countertop fabricators across California have filed hundreds of product liability suits alleging manufacturers concealed the severity of airborne hazards.
- The jury awarded $25M in noneconomic damages and $8M for loss of consortium, firmly rejecting Caesarstone's claim that fabrication shops bore sole safety responsibility.
- Caesarstone was allocated 22% comparative fault, meaning net damages will be determined after offsets from prior settlements with other stone distributors.
- With five plaintiff verdicts in six trials, insurers are tightening coverage limits, accelerating calls for statewide bans on high-silica artificial slabs.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
